EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative Outcomes and Side Effects of Immunosuppressants and Tumor Necrosis Factor Inhibitors in Sarcoidosis

Wen-Cheng Chao, Shu-Yi Liao

CHEST · 2026

DOI: 10.1016/j.chest.2025.09.130 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift CHEST, 2026. Verfasst von Wen-Cheng Chao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Post-Baccalaureate Medicine, College of Med…. Hauptthemen laut MEDLINE: Immunosuppressive Agents, Sarcoidosis, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, Foundation for Sarcoidosis Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Sarcoidosis is a complex systemic granulomatous disease with varying clinical manifestations, and immunosuppressive agents and tumor necrosis factor (TNF) inhibitors have been used in severe and refractory cases. However, the comparison of the serious side effects of these treatments remains poorly understood. RESEARCH QUESTION: In sarcoidosis, what is the 1-year risk of serious side effects among second-line agents (immunosuppressants) and TNF inhibitors? STUDY DESIGN AND METHODS: A retrospective analysis of data from the TriNetX Research Network, which includes de-identified medical records of patients with sarcoidosis treated with specific immunosuppressive agents or TNF inhibitors between 2012 and 2023 across 82 health care organizations. Propensity score matching (PSM) was used to mitigate confounding effects. RESULTS: A total of 13,814 patients receiving immunosuppressive agents were included. We found that patients who received mycophenolate mofetil (MMF) showed higher risks for inpatient hospitalization (hazard ratio [HR], 2.74; 95% CI, 2.11-3.56), critical care (HR, 2.37; 95% CI, 1.91-2.94), mechanical ventilation (HR, 4.04; 95% CI, 2.630-6.21), mortality (HR, 2.16; 95% CI, 1.70-2.75), and infections compared with those who received methotrexate. Azathioprine use showed increased risks for mortality, hematologic toxicity, and infections compared with methotrexate use. Among the 3,964 patients with sarcoidosis receiving TNF inhibitors, we found similar rare occurrence of serious side effects between infliximab and adalimumab, although a slightly higher risk of anemia (HR, 1.81; 95% CI, 1.22-2.67), thrombocytopenia (HR, 2.67; 95% CI, 1.75-4.07), and pneumonia (HR, 1.47; 95% CI, 1.02-2.10), but lower risk of skin soft tissue infection (HR, 0.39; 95% CI, 0.17-0.89) in the infliximab group. INTERPRETATION: We used large real-world data with a PSM approach to demonstrate the heightened risk of infection and bone marrow suppression with MMF compared with the other immunosuppressants and a similar rate of serious side effects between infliximab and adalimumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunosuppressive AgentsSarcoidosisTumor Necrosis Factor InhibitorsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultPropensity ScoreInfliximabAdalimumabTumor Necrosis Factor-alphaMycophenolic AcidMethotrexate

Stichwörter der Autor:innen

immunosuppressantsreal-world studysarcoidosisside effectstumor necrosis factor inhibitors

Substanzen

Immunosuppressive AgentsTumor Necrosis Factor InhibitorsInfliximabAdalimumabTumor Necrosis Factor-alphaMycophenolic AcidMethotrexate

Autor:innen und Institutionen

  • Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Post-Baccalaureate Medicine, College of Medicine, Taichung, Taiwan; Big Data Center, National Chung Hsing Univers…
  • Department of Medicine, National Jewish Health, Denver, CO; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; Colorado School of Public Health, University of Colorado Anschutz Medical C…

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute
  • Foundation for Sarcoidosis Research
  • National Institutes of Health

Zitieren

APA

Chao, W. C., & Liao, S. Y. (2026). Comparative Outcomes and Side Effects of Immunosuppressants and Tumor Necrosis Factor Inhibitors in Sarcoidosis. CHEST. https://doi.org/10.1016/j.chest.2025.09.130

Vancouver

Chao WC, Liao SY. Comparative Outcomes and Side Effects of Immunosuppressants and Tumor Necrosis Factor Inhibitors in Sarcoidosis. CHEST. 2026. doi:10.1016/j.chest.2025.09.130

BibTeX
@article{Chao2026,
  author = {Chao, Wen-Cheng and Liao, Shu-Yi},
  title = {Comparative Outcomes and Side Effects of Immunosuppressants and Tumor Necrosis Factor Inhibitors in Sarcoidosis},
  journal = {CHEST},
  year = {2026},
  doi = {10.1016/j.chest.2025.09.130}
}
Kostenlos starten →